Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBagshaw, Sean M-
dc.contributor.authorGibney, RT Noel-
dc.contributor.authorKruger, Peter-
dc.contributor.authorHassan, Imran-
dc.contributor.authorMcAlister, Finlay A-
dc.contributor.authorBellomo, Rinaldo-
dc.identifier.citationJournal of Critical Care 2017; 42: 138-146en_US
dc.description.abstractPURPOSE: Furosemide is commonly prescribed in acute kidney injury (AKI). Prior studies have found conflicting findings on whether furosemide modifies the course and outcome of AKI. METHODS: Pilot multi-center randomized blinded placebo-controlled trial in adult patients with AKI admitted to three intensive care units. Participants were randomly allocated to furosemide bolus and infusion or 0.9% saline placebo. Primary endpoint was worsening AKI, defined by the RIFLE criteria. Secondary endpoints were kidney recovery, renal replacement therapy (RRT) and adverse events. RESULTS: The trial was terminated after enrollment of 73 participants (37 to furosemide and 36 to placebo). Mean (SD) age was 61.7 (14.3), 79.5% were medical admissions, mean (SD) APACHE II score was 26.6 (7.8), 90.4% received mechanical ventilation and 61.6% received vasoactives. Groups were similar at baseline. No differences were found in the proportion with worsening AKI (43.2% vs. 37.1%, p=0.6), kidney recovery (29.7% vs. 42.9%, p=0.3), or RRT (27.0% s. 28.6%, p=0.8). Adverse events, mostly electrolyte abnormalities, were more common in furosemide-treated patients (p<0.001). Protocol deviations were common, due often to supplementary furosemide. CONCLUSIONS: In this pilot trial, furosemide did not reduce the rate of worsening AKI, improve recovery or reduce RRT; however, was associated with greater electrolyte abnormalities. TRIAL REGISTRATION: Identifier: NCT00978354 registered September 9, 2014.en_US
dc.subjectAcute kidney injuryen_US
dc.subjectRenal replacement therapyen_US
dc.subjectUrine outputen_US
dc.titleThe effect of low-dose furosemide in critically ill patients with early acute kidney injury: a pilot randomized blinded controlled trial (the SPARK study)en_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleJournal of Critical Careen_US
dc.identifier.affiliationDepartment of Critical Care Medicine, Faculty of Medicine and Dentistry, University of Alberta, Clinical Science Building, Edmonton, Alberta, Canadaen_US
dc.identifier.affiliationDepartment of Intensive Care Medicine, Princess Alexandra Hospital, Woolloongabba, Queensland, Australiaen_US
dc.identifier.affiliationSchool of Medicine, University of Queensland, Queensland, Australiaen_US
dc.identifier.affiliationEpidemiology Coordinating and Research Centre (EPICORE), Department of Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canadaen_US
dc.identifier.affiliationDivision of General Internal Medicine, Faculty of Medicine and Dentistry, University of Alberta, Clinical Science Building, Edmonton, Alberta, Canadaen_US
dc.identifier.affiliationDepartment of Intensive Care, Austin Health, Heidelberg, Victoria, Australiaen_US
dc.type.austinJournal Articleen_US, Rinaldo
item.fulltextNo Fulltext-
item.openairetypeJournal Article-
item.grantfulltextnone- Care- Analytics Research and Evaluation (DARE) Centre-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

checked on Jun 14, 2024

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.